Activation of the MEK pathway is required for complete scattering of MCF7 cells stimulated with heregulin-β1

Chang, Yu-Tsu; Shu, Chung-Li; Fukui, Yoshihiro

doi:10.1016/j.bbrc.2013.02.103

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings could explain the high frequency of metastasis and reoccurrence in gastric SRCC. In our study, the proportion of gastric cancer patients with distant metastasis was significantly higher in SRCC than in NOS (43.31% vs 34.08%, P < .001), which was consistent with the pathological features of SRCC reported by previous studies . However, further clinical and genetic analyses are still needed to establish improved therapeutic management of these stage IV patients.…”

Section: Discussionsupporting

confidence: 91%

“…It has been shown that the activation of PI3K (Phosphoinositide 3‐kinase) through the ErbB2 (Her2)/ ErbB3 (Her3) pathway in signet ring cells could enhance mucin secretion . Additionally, the adherent junction is disrupted via activation of the Mitogen‐activated protein kinase 1 (MEK1) pathway, which leads to the loss of cell‐cell contact . Further, it has been reported that signet ring cells were more likely to have transcoelomic metastasis than other gastric cancer cells .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population‐based study

et al. 2019

View full text Add to dashboard Cite

Background Stage IV gastric signet ring cell carcinoma (SRCC) is a type of malignant gastric cancer (GC) with poorer survival compared to metastatic non‐SRCC gastric cancer (NOS). However, chemotherapy alone was unable to maintain long‐term survival. This study aimed to evaluate survival benefit of palliative gastrectomy plus chemotherapy (PG+C) for metastatic gastric SRCC. Methods We obtained data on gastric cancer patients between 2010 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. Statistical methods included χ2 tests, Kaplan‐Meier curves, COX models, propensity score matching (PSM) and subgroup analysis. Results Among 27 240 gastric cancer patients included, 4638 (17.03%) were SRCC patients. The proportion of patients with younger age, female gender, poorly differentiated grade and M1 stage was higher in SRCC than in NOS (P < .001). Multivariate analysis revealed that multiple metastatic sites (HR = 1.39, 95% CI: 1.14‐1.69, P = .001) was associated with increased mortality risk in metastatic SRCC. Median survival time was improved in metastatic SRCC receiving PG+C compared to PG/C alone (13 vs 7 months, P < .001). Notably, in subgroup analysis, 13 of 17 groups of metastatic SRCC patients with PG+C had prolonged overall survival compared to chemotherapy alone, especially for those with only one metastatic site (HR = 0.61, 95% CI: 0.51‐0.73, P < .001). Conclusions Our results suggested that there exists at least a selective group of stage IV gastric SRCC patients, who could benefit from palliative gastrectomy followed by chemotherapy compared to chemotherapy alone. Further prospective trials are needed to support our conclusion.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%